First UK Patient Received Revolutionary EASEE® Implant

Precisis is proud to announce a significant milestone in epilepsy treatment with the first UK patient undergoing surgery to fit the revolutionary EASEE® implant at the Royal Infirmary in Newcastle. Mr. Chris Cowie, neurosurgeon at the Royal Victoria Infirmary, explains, "We can fit this implant in less than an hour, potentially changing lives for patients with certain types of epilepsy. It has shown to reduce the severity and incidence of seizures in patients across Europe."

Karl Stoklosa, CEO of Precisis, expressed his excitement, "We are delighted to partner with Newcastle Hospitals to bring the first EASEE® implant to the UK. This is a crucial step in providing more treatment options for epilepsy patients on the NHS."

The EASEE® implant represents the future of epilepsy treatment, with potential applications for other functional neurological diseases. As technology advances, these implants are becoming more effective, offering hope to many.

The surgery at the Royal Infirmary in Newcastle marks a pivotal moment in the ongoing efforts to improve the quality of life for epilepsy patients. The EASEE® implant is designed to be less invasive than other options, making the procedure less daunting for patients and allowing for quicker recovery times. This innovative approach to epilepsy treatment is part of a broader movement towards personalized medicine, where treatments are tailored to the specific needs of individual patients.

The successful implementation of the EASEE® implant at the Royal Infirmary in Newcastle is a significant development for the UK population. It underscores the commitment to providing cutting-edge treatments to those who need them most, offering new hope and improved quality of life for epilepsy patients across the country. This milestone is expected to enhance the standard of care available within the NHS, ensuring that patients have access to the latest advancements in medical technology.

As the first EASEE® implant is successfully fitted in the UK, Precisis remains committed to expanding access to this revolutionary treatment. The company is dedicated to ongoing research and development to enhance the effectiveness of the implant and explore its potential applications beyond epilepsy. This milestone is just the beginning of a new era in epilepsy treatment, offering renewed hope to patients and their families.